Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Inclusion Criteria: * Males and females \> 18 years of age * Life expectancy of at least 2 months * Histologically confirmed unresectable malignant pleural mesothelioma (MPM) * Measurable disease by CT Scan criteria and/or positive metabolic activity of 18F-FDG PET Scan criteria at screening * ECOG Performance Status of 0-2 * Laboratory and clinical results within 2 weeks prior to Day 1 must be as follows: 1. ANC ≥ 1.5 x 109/L 2. Platelet Count ≥ 100 x 109/L 3. Hemoglobin ≥ 9g/dL 4. Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) 5. AST ≤ 2.5 x ULN 6. ALT ≤ 2.5 x ULN 7. ALK-P ≤ 3 x ULN 8. Serum creatinine ≤ 1.8mg/dL 9. Calculated Serum Creatinine Clearance 40 - \> 60ml/min * Female subjects of childbearing potential and all male subjects must be surgically sterile or consent to use a medically acceptable method of contraception throughout the trial. * Willing and able to provide written informed consent. Exclusion Criteria: * Known central nervous system (CNS) tumor involvement * Evidence of other active malignancy requiring treatment * Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class 3 or 4 angina not well controlled by medication, or myocardial infarction within 6 months) * Known infection with HIV or hepatitis * Clinically significant arrhythmias demonstrated on electrocardiogram (ECG). Note: subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia (SVT) are eligible. * Active, serious systemic disease, including active bacterial or fungal infection. * Subjects undergoing invasive dental procedures, significant periodontal disease or history of osteonecrosis of the jaw. * Treatment within 4 weeks of the start of the trial with other systemic anticancer therapy. * Breastfeeding, pregnant, or likely to become pregnant during the clinical trial.